NASDAQ:VERU - Veru Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $2.08 +0.02 (+0.97 %) (As of 07/15/2018 03:06 PM ET)Previous Close$2.08Today's Range$2.05 - $2.1052-Week Range$0.90 - $3.00Volume40,772 shsAverage Volume162,423 shsMarket Capitalization$111.31 millionP/E RatioN/ADividend YieldN/ABeta0.66 Company ProfileFinancialsAnalyst RatingsDividend HistoryEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Veru Inc. operates as a urology and oncology biopharmaceutical company. The company operates through two segments, Commercial; and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation. The company's urology drug candidates include Tamsulosin delayed release sachet and Tamsulosin XR capsules that are under bioequivalence study for the treatment of benign prostatic hyperplasia; and Solifenacin delayed release granules, which are under bioequivalence study for the treatment of overactive bladder. Its urology drug candidates also comprise Tadalafil-Finasteride combination capsules that are under bioequivalence study for the treatment of men with lower urinary tract symptoms and enlarged prostate; VERU-944, which is in Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and VERU-722 that is in Phase II clinical trial for the treatment of male infertility caused by testicular dysfunction. The company's oncology drug candidate is VERU-111, a novel oral alpha and beta tubulin inhibitor, which is under preclinical study for the treatment of metastatic prostate, breast, endometrial, ovarian, and other cancers. It also develops VERU-111/VERU-112, a novel oral agent targeting colchicine binding site that is under preclinical study for the treatment of gout and familial mediterranean fever. Veru Inc. serves agencies, non-government organizations, ministries of health, and other governmental agencies through distributors and retailers primarily in the United States, Brazil, Spain, France, and the United Kingdom. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was founded in 1896 and is headquartered in Miami, Florida. Receive VERU News and Ratings via Email Sign-up to receive the latest news and ratings for VERU and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Fabricated rubber products, not elsewhere classified Sub-IndustryPersonal Products SectorMedical SymbolNASDAQ:VERU CUSIP31446210 Webwww.veruhealthcare.com Phone305-509-6897 Debt Debt-to-Equity Ratio0.14 Current Ratio1.53 Quick Ratio1.19 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$13.66 million Price / Sales8.15 Cash FlowN/A Price / CashN/A Book Value$0.91 per share Price / Book2.29 Profitability EPS (Most Recent Fiscal Year)($0.25) Net Income$-6,610,000.00 Net Margins-87.78% Return on Equity-21.72% Return on Assets-16.38% Miscellaneous Employees175 Outstanding Shares53,510,000Market Cap$111.31 Veru (NASDAQ:VERU) Frequently Asked Questions What is Veru's stock symbol? Veru trades on the NASDAQ under the ticker symbol "VERU." How were Veru's earnings last quarter? Veru Inc (NASDAQ:VERU) announced its earnings results on Wednesday, May, 9th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by $0.02. The firm earned $2.57 million during the quarter, compared to analyst estimates of $7.60 million. Veru had a negative net margin of 87.78% and a negative return on equity of 21.72%. View Veru's Earnings History. When is Veru's next earnings date? Veru is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Veru. What price target have analysts set for VERU? 4 analysts have issued 12-month price objectives for Veru's stock. Their forecasts range from $5.00 to $5.00. On average, they anticipate Veru's share price to reach $5.00 in the next year. This suggests a possible upside of 140.4% from the stock's current price. View Analyst Ratings for Veru. What is the consensus analysts' recommendation for Veru? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veru in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." What are Wall Street analysts saying about Veru stock? Here are some recent quotes from research analysts about Veru stock: 1. Maxim Group analysts commented, "We are initiating coverage of Veru Inc. with a $10 price target. Veru is a commercial-stage company (female/male health) with a pipeline of both 505(b)(2) and novel products that address benign prostatic hyperplasia (BPH), overactive bladder (OAB), and prostate cancer (PC)." (7/3/2018) 2. According to Zacks Investment Research, "Veru Inc. engages in the development, manufacture and marketing of consumer health care products. It focuses on producing FC2 female condom which provides dual protection against unintended pregnancy and sexually transmitted infections. Veru Inc., formerly known as The Female Health Company, is headquartered in Miami, FL. " (5/16/2018) Who are some of Veru's key competitors? Some companies that are related to Veru include ZIOPHARM Oncology (ZIOP), CareDx (CDNA), Senseonics (SENS), Achillion Pharmaceuticals (ACHN), Antares Pharma (ATRS), Neuronetics (STIM), OrganiGram (OGRMF), Evelo Biosciences (EVLO), Albireo Pharma (ALBO), Georgia Healthcare Group (GHG), American Brivision (Holding) (ABVC), Pharma Mar (PHMMF), Syros Pharmaceuticals (SYRS), Concert Pharmaceuticals (CNCE) and Clementia Pharmaceuticals (CMTA). Who are Veru's key executives? Veru's management team includes the folowing people: Mr. O. B. Parrish, Co-Founder & Vice Chairman (Age 85)Ms. Michele Greco, CFO, Exec. VP of Fin. & Chief Admin. Officer (Age 59)Dr. Harry Fisch, Chief Corp. Officer & Director (Age 59)Dr. Mitchell S. Steiner, Pres, CEO & Director (Age 57)Mr. Kevin J. Gilbert, Sr. VP of Corp. Devel. & Legal and Sec. Has Veru been receiving favorable news coverage? Media stories about VERU stock have been trending somewhat positive this week, according to Accern. The research firm rates the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Veru earned a news sentiment score of 0.13 on Accern's scale. They also gave news articles about the company an impact score of 46.76 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. How do I buy shares of Veru? Shares of VERU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Veru's stock price today? One share of VERU stock can currently be purchased for approximately $2.08. How big of a company is Veru? Veru has a market capitalization of $111.31 million and generates $13.66 million in revenue each year. The company earns $-6,610,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis. Veru employs 175 workers across the globe. How can I contact Veru? Veru's mailing address is 4400 Biscayne Boulevard Suite 888, Miami FL, 33137. The company can be reached via phone at 305-509-6897 or via email at [email protected] MarketBeat Community Rating for Veru (NASDAQ VERU)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 119 (Vote Outperform)Underperform Votes: 68 (Vote Underperform)Total Votes: 187MarketBeat's community ratings are surveys of what our community members think about Veru and other stocks. Vote "Outperform" if you believe VERU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VERU will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/15/2018 by MarketBeat.com StaffFeatured Article: What are Closed-End Mutual Funds?